Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma.
Hultcrantz M, Hassoun H, Korde N, MacLachlan K, Mailankody S, Patel D, Shah UA, Tan CR, Chung DJ, Lahoud OB, Landau HJ, Scordo M, Shah GL, Giralt SA, Pianko MJ, Burge M, Barnett K, Salcedo M, Caple J, Tran L, Blaslov J, Shekarkhand T, Hamid S, Nemirovsky D, Derkach A, Arisa O, Peer CJ, Figg WD, Usmani SZ, Landgren O, Lesokhin AM. Hultcrantz M, et al. Among authors: shekarkhand t. Blood Cancer J. 2024 Sep 19;14(1):164. doi: 10.1038/s41408-024-01136-1. Blood Cancer J. 2024. PMID: 39300066 Free PMC article. No abstract available.
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma.
Hultcrantz M, Hassoun H, Korde N, Maclachlan K, Mailankody S, Patel D, Shah U, Tan CR, Chung DJ, Lahoud O, Landau H, Scordo M, Shah GL, Giralt S, Pianko MJ, Burge M, Barnett K, Salcedo M, Caple J, Tran L, Blaslov J, Shekarkhand T, Hamid S, Nemikovski D, Derkach A, Arisa O, Peer CJ, Figg WD, Usmani SZ, Landgren O, Lesokhin AM. Hultcrantz M, et al. Among authors: shekarkhand t. Res Sq [Preprint]. 2024 Jun 5:rs.3.rs-4406606. doi: 10.21203/rs.3.rs-4406606/v1. Res Sq. 2024. Update in: Blood Cancer J. 2024 Sep 19;14(1):164. doi: 10.1038/s41408-024-01136-1 PMID: 38883739 Free PMC article. Updated. Preprint.
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, Farzana T, Rueda C, Chung DJ, Landau HJ, Lahoud OB, Scordo M, Shah GL, Hassoun H, Maclachlan K, Korde N, Shah UA, Tan CR, Hultcrantz M, Giralt SA, Usmani SZ, Shahid Z, Mailankody S, Lesokhin AM. Nath K, et al. Among authors: shekarkhand t. Blood Cancer J. 2024 May 31;14(1):88. doi: 10.1038/s41408-024-01043-5. Blood Cancer J. 2024. PMID: 38821925 Free PMC article.
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Firestone RS, Socci ND, Shekarkhand T, Zhu M, Qin WG, Hultcrantz M, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah U, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Usmani SZ, Chung DJ. Firestone RS, et al. Among authors: shekarkhand t. Blood. 2024 Jul 25;144(4):402-407. doi: 10.1182/blood.2023023557. Blood. 2024. PMID: 38728378
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.
Hamadeh IS, Shekarkhand T, Rueda C, Firestone RS, Wang AX, Korde N, Hultcrantz ML, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Patel D, Shah GL, Scordo M, Lahoud OB, Chung DJ, Landau HJ, Giralt S, Usmani SZ, Tan CR. Hamadeh IS, et al. Among authors: shekarkhand t. Blood Adv. 2024 Jun 25;8(12):3038-3044. doi: 10.1182/bloodadvances.2024012724. Blood Adv. 2024. PMID: 38598713 Free PMC article.
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
Lesokhin A, Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, Farzana T, Rueda C, Chung D, Landau H, Lahoud O, Scordo M, Shah G, Hassoun H, Maclachlan K, Korde N, Shah U, Tan CR, Hultcrantz M, Giralt S, Usmani S, Shahid Z, Mailankody S. Lesokhin A, et al. Among authors: shekarkhand t. Res Sq [Preprint]. 2024 Feb 7:rs.3.rs-3911922. doi: 10.21203/rs.3.rs-3911922/v1. Res Sq. 2024. Update in: Blood Cancer J. 2024 May 31;14(1):88. doi: 10.1038/s41408-024-01043-5 PMID: 38405866 Free PMC article. Updated. Preprint.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Firestone RS, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, Zhu M, Qin WG, Patel D, Tan CR, Hultcrantz M, Mailankody S, Hassoun H, Shah US, Korde N, Maclachlan KH, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Hosszu KK, Chung DJ, Lesokhin AM, Usmani SZ. Firestone RS, et al. Among authors: shekarkhand t. Blood Adv. 2024 Apr 9;8(7):1600-1611. doi: 10.1182/bloodadvances.2023011225. Blood Adv. 2024. PMID: 37878808 Free PMC article.
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.
Nath K, Shekarkhand T, Salcedo M, Derkach A, Rueda S, Chansakul A, Hulcrantz M, Korde N, Shah UA, Tan C, Chung DJ, Lahoud OB, Hassoun H, Lesokhin AM, Landau HJ, Shah G, Scordo M, Giralt SA, Usmani SZ, Roshal M, Landgren O, Mailankody S. Nath K, et al. Among authors: shekarkhand t. Leuk Lymphoma. 2022 Dec;63(14):3488-3492. doi: 10.1080/10428194.2022.2131417. Epub 2022 Oct 25. Leuk Lymphoma. 2022. PMID: 36282633 No abstract available.
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.
Shah UA, Maclachlan KH, Derkach A, Salcedo M, Barnett K, Caple J, Blaslov J, Tran L, Ciardiello A, Burge M, Shekarkhand T, Adintori P, Cross J, Pianko MJ, Hosszu K, McAvoy D, Mailankody S, Korde N, Hultcrantz M, Hassoun H, Tan CR, Lu SX, Patel D, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, Usmani SZ, Giralt S, Taur Y, Landgren CO, Block G, Block T, Peled JU, van den Brink MRM, Lesokhin AM. Shah UA, et al. Among authors: shekarkhand t. Clin Cancer Res. 2022 Dec 1;28(23):5149-5155. doi: 10.1158/1078-0432.CCR-22-0723. Clin Cancer Res. 2022. PMID: 36170461 Free PMC article.
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, Mailankody S, Hassoun H, Tan C, Shah UA, Lu SX, Salcedo M, Werner K, Rispoli J, Caple J, Sams A, Verducci D, Jones K, Concepcion I, Ciardello A, Chansakul A, Schlossman J, Tavitian E, Shekarkhand T, Harrison A, Piacentini C, Rustad EH, Yellapantula V, Maclaughlan K, Maura F, Landau HJ, Scordo M, Chung DJ, Shah G, Lahoud OB, Thoren K, Murata K, Ramanathan L, Arcila ME, Ho C, Roshal M, Dogan A, Derkach A, Giralt SA, Korde N. Landgren O, et al. Among authors: shekarkhand t. JAMA Oncol. 2021 Jun 1;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611. JAMA Oncol. 2021. PMID: 33856405 Free PMC article. Clinical Trial.